 DARTMOUTH, Nova Scotia--BUSINESS WIRE--IMV Inc. Nasdaq: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that updated clinical data from phase 2 SPiReL study evaluating IMVs T cell therapy in combination with Mercks Keytruda in patients with relapsed refractory Diffuse Large B Cell Lymphoma rr DLBCL will be presented at the American Society of Hematology ASH Annual 